Metabolic drugs for HS? GLP‑1 receptor agonists show promise beyond weight loss If you haven’t yet, dig into this recent JDD article about GLP-1 receptor agnosists and hidradenitis suppurativa. Hidradenitis…
Read More
Representation improving but not solved—Black patients still underrepresented in recent HS trials A review of ClinicalTrials.gov trials for hidradenitis suppurativa initiated between June 2020 and December 2024 identified five trials…
Read More
What patients eat matters in HS: pro‑inflammatory diets worsen disease; anti‑inflammatory patterns and targeted supplements may help This literature review synthesizes recent studies connecting dietary patterns with hidradenitis suppurativa severity.…
Read More
Moderate Evidence Points To Safety And Quality-Of-Life Gains In Hard-To-Treat Patients We’re pulling this article from our vault because it’s one of our most popular reads, and with good reason.…
Read More
Botulinum Toxin for Hidradenitis Suppurativa? Early Evidence Looks Promising Hidradenitis suppurativa (HS) remains a challenging and often painful condition—one that disproportionately affects women, people of color, and underserved populations. With…
Read More
Has TikTok Helped Your Patients Recognize Hidradenitis Suppurativa Sooner? You might have heard it from your own patients: “I saw a video on TikTok and realized I might have HS.”…
Read More
